Latin American guidelines on hypertension

Journal of Hypertension

Volumn 27, Issue 5, 2009, Pages 905-922

  Sanchez, Ramiro A ^a,b   Ayala, Miryam ^a   Baglivo, Hugo ^a   Velazquez, Carlos ^a   Burlando, Guillermo ^a   Kohlmann, Oswaldo ^a   Jimenez, Jorge ^a   Jaramillo, Patricio López ^a   Brandao, Ayrton ^a   Valdes, Gloria ^a   Alcocer, Luis ^a   Bendersky, Mario ^a   Ramirez, Agustín José ^a   Zanchetti, Alberto ^a  

^a Latin America Expert Group   (United States)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Diabetes; Diagnosis; Epidemiology; Hypertension; Special populations; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; NEBIVOLOL; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

ANAMNESIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BREAST FEEDING; CALCIUM INTAKE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; ECLAMPSIA; GLYCEMIC CONTROL; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HELLP SYNDROME; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LABORATORY TEST; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MATERNAL HYPERTENSION; METABOLIC SYNDROME X; MORTALITY; PATIENT ATTITUDE; PATIENT EDUCATION; PHYSICAL EXAMINATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SOUTH AND CENTRAL AMERICA; STROKE; SYSTOLIC HYPERTENSION; WHITE COAT HYPERTENSION; WORLD HEALTH ORGANIZATION;

EID: 67649828062     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832aa6d2     Document Type: Review

References (157)

1. Lawes CMM, Vander Horn S, Rodgers A, for the International Society of Hypertension. Global burden of blood pressure-related disease 2001. Lancet 2008; 371:1513-1518.
2. WHO. The World Health Report, 2002: reducing risks, promoting healthy life. Geneva: World Health Organization; 2003.
3. World Health Organization. Report of the Commission Macroeconomics and Health: investing in health for economic development. Geneva: WHO; 2001. http://www.who.int/cardiovascular-diseases/guidelines/Full%20text.pdf.
4. Prevention of Cardiovascular Disease. Guidelines for assessment and management of Cardiovascular Risk (with CD-ROM nonserial publication World Health Organization ISBN-13 9789241547178: http://www.who.int/cardiovascular- diseases/guidelines/Full%20text.pdf).
5. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension, The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
6. Burlando G, Sanchez R, Ramos F, Mogensen C, Zanchetti A, on behalf of the Latin American Experts Group. Latin American consensus on diabetes mellitus and hypertension. J Hypertens 2004; 22:2229-2241.
7. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, Yusuf S, INTERHEART Investigators in Latin America. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007; 115:1067-1074.
8. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Latin America. Nutr Rev 2001; 59:170-176.
9. Sereday MS, Gonzalez C, Giorgini D, De Loredo L, Braguinsky J, Cobeñas C, et al. Prevalence of diabetes and obesity in the central area of Argentina. Diabetes Metab 2004; 30:335-339.
10. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality, disability from diseases, injuries, risk factors in 1990, projected to 2020. Boston, Massachusetts: Harvard School of Public Health; 1996.
11. MacMahon S, Alderman MH, Lindholm LH, Liu L, Sánchez RA, Seedat YK. Blood-pressure-related disease is a global health priority. Lancet 2008; 1:1480-1482.
12. Reddy KS, Yusuf S. Emerging epidemics of cardiovascular disease in developing countries. Circulation 1998; 97:596-660.
13. Jamison DT. Investing in health. In Disease control priorities in developing countries, 2nd ed. New York: Oxford University Press; 2006. pp. 3-36.
14. Lopez-Jaramillo P. Defining the research priorities to fight the burden of cardiovascular diseases in Latin America. J Hypertens 2008; 26:1886-1889.
15. Actuarial Society of America and the Association of Life Insurance Medical Directors. Supplement to blood pressure study. New York: Actuarial Society of America; 1941.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al., and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003; 289:2560-2572.
17. Latin American Consensus on Arterial Hypertension. J Hypertens [Spanish ed.] 2001; 6:01-110.
18. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152:56-64.
19. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153:598-615.
20. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19:2063-2070.
21. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
22. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 1988; 259:225-228.
23. Julius S, Mejia A, Jones K, Krause L, Sork N, Van de Ven C, et al. White coat versus sustained borderline hypertension in Tecumseh, Michigan. Hypertension 1990; 16:617-623.
24. Robles NR, Cancho B. Hipertensión de bata blanca. Nefrologia 2002; 22(Supl 3):72-76.
25. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47: 846-853.
26. Ohkubo T, Kiluya M, Metoki H, Asayama K, Obara T, Hashimoto T, et al. Prognosis of masked hypertension and white-coat hypertension detected by 24 h ambulatory blood pressure monitoring. J Am Coll Cardiol 2005; 46:508-515.
27. Fagard RH, Den Broski G, De Cort P. Diagnostic significance of blood pressure measurement in the office, at home and during ambulatory monitoring in older patients in general population. J Hum Hypertens 2005; 19:801-807.
28. Sega R, Tromino G, Lanzarotti A, Carugo S, Cesana G, Sciavoni R, et al. Alterations in cardiac structure in patients with isolated office, ambulatory or home hypertension. Data from the general PAMELA population. Circulation 2001; 1104:1385-1392.
29. Bordley J III, Connor CAR, Hamilton WF, Kerr WJ, Wiggers CJ. Recommendations for human blood pressure determinations by sphygmomanometers. Circulation 1951; 4:503-509.
30. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, et al., on behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008; 26:1505-1526.
31. Palatini P. Ambulatory blood pressure monitoring in clinical practice: is being superior good enough? J Hypertens 2008; 26:1300-1302.
32. White WB. Ambulatory blood pressure monitoring in clinical practice." EnglJ Med 2003; 348:2377-2378.
33. Asociación LatinoAmericana de Diabetes. Guias ALAD 2002 para el Diagnostico y Manejo de la Diabetes Mellitus tipo 2 con Medicina basada en Evidencia. http://www.fenadiabetes.org.ve/docs/guia.pdf.
34. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26:575-581.
35. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. Circulation 2004; 109:42-46.
36. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
37. López-Jaramillo P, Rueda-Clausen C, Silva FA. The utility of different definitions of metabolic syndrome in Andean population. Int J Cardiol 2007; 116:421-422.
38. Garcia RG, Cifuentes AE, Caballero RS, Sanchez L, López-Jaramillo P. A Proposal for an appropriate central obesity diagnosis in Latin American population. Int J Cardiol 2005; 110:263-264.
39. Pérez M, Casas JP, Cubillos LA, Serrano NC, Silva FA, Morillo CA, López-Jaramillo P. Using waist circumference as screening tool to identify colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2003; 10:328-335.
40. The DREAM trial investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551-1562.
41. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2001.
42. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-1214.
43. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233-240.
44. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 25:2147-2155.
45. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case control study. J Am Coll Cardiol 1999; 33:612-619.
46. Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asian Pacific region. Diabetes Care 2004; 27:2836-2842.
47. Lopez-Jaramillo P, Pradilla LP, Castillo V, Lahera V. Socio-economical pathology as determinant of regional differences in the prevalence of metabolic syndrome and pregnancy-induced hypertension. Rev Esp Cardiol 2007; 60:168-178.
48. ADA Clinical Practice Recommendations. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(Suppl 1):S5-S10.
49. Sawicki PT, Mülhauser I, Didjurgeit U, Reimann M, Bender R, Berger M. Mortality and morbidity in treated hypertensive type 2 diabetic patients with micro-proteinuria. Diabetic Med 1995; 12:893-898.
50. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37:1053-1059.
51. James WPT, Jackson-Leach R, Mhurdu CN, Kalamara E, Shayeghi M, Rigby N, et al. Overweight and obesity. In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, editors. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: WHO; 2003.
52. Eriksson H, Welim L, Wilhelmsen L, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Metabolic disturbances in hypertension: results from the population study: 'men born in 1913'. J Intern Med 1992; 232:389-395.
53. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, et al. Development and progression of renal disease in Pima Indians with noninsulin-dependent diabetes mellitus. N Engl J Med 1996; 335:1636-1642.
54. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36:646-661.
55. DeFronzo RA. Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995; 3:510-564.
56. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
57. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, etal., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
58. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, et al., Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41:1063-1071.
59. The ONTARGET Investigators. Telmisartan, ramipril or both in patients with high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
60. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124:627-632.
61. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta analysis of prospective studies. Diabetes Care 2000; 23:962-968.
62. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet 2006; 368:29-36.
63. Colwell JA. Aspirin therapy in diabetes [technical review]. Diabetes Care 1997; 20:1767-1771.
64. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, etal. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
65. Bonow RO, Mitch WE, Nesto RW, O'Gara PT, Becker RC, Clark LT, et al. Prevention conference VI. Diabetes and Cardiovascular disease. Writing Group V: management of cardiovascular-renal complications. Circulation 2002; 105:e159-e164.
66. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-833.
67. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive HF: the Framingham study. Am J Cardiol 1974; 34:29-34.
68. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycaemic control and HF among adult patients with diabetes. Circulation 2001; 103:2668-2673.
69. Bell DS. The frequent, forgotten and often fatal complication of diabetes. Diabetes Care 2003; 26:2433-2441.
70. Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, et al. The relationship between left ventricular function and congestive HF diagnosed by clinical criteria. Circulation 1988; 77:607-612.
71. Kasrapanayiotides T, Piechowski-Jozwiak B, Van Melle G, Bogousslavsky J, Devuyst G. Stroke patterns, etiology and prognosis in patients with diabetes mellitus. Neurology 2004; 62:1558-1562.
72. Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Protect. Stroke 2003; 34:688-694.
73. Consenso de Hipertensión Arterial. Rev Argent Cardiol 2007; 75(Suppl 3):1-43.
74. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
75. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type diabetes (UKPDS). Lancet 1998; 352:837-853.
76. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
77. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
78. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L, for the DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 29:166-1 76.
79. Garcia RG, Lopez-Jaramillo P. Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it? Eur Heart J 2008; 29:2058-2059.
80. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Athersclerosis Risk in Communities study. N Engl J Med 2000; 342:905-912.
81. Carlsson PO, Berne C, Jansson L Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998; 41:127-133.
82. Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 1994; 24 (Suppl 3):S61-S69.
83. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996; 93:12490-12495.
84. Esler M. Differentiation in the effects of the angiotensin II receptor blocker class on autonomic function. J Hypertens Suppl 2002; 20:S13-S19.
85. Torlone E, Rambotti AM, Perriello G, Botta G, Santeusanio F, Brunetti P, Bolli GB. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (noninsulin-dependent) diabetes mellitus and arterial hypertension. Diabetologia 1991; 34:119-125.
86. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28:2261-2266.
87. Elliott WJ, Meier PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
88. Lopez-Jaramillo P, Pradilla LP, Lahera V, Silva F, Rueda-Clausen C, Marquez G. A randomized, double blind, cross-over, placebo-controlled clinical trial to assesss the effects of Candesartan on the insulin sensitivity on non diabetic, non hypertenive subjects with dysglycemia and abdominal obesity. ARAMIA. Trials 2006; 7:28-39.
89. Lopez-Jaramillo P, Garcia G, Camacho PA, Herrera E, Castillo V. Interrelationship between body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am J Hypertens 2008; 21:527-532.
90. López-Jaramillo P, Silva SY, Rodríguez Salamanca N, Duran A, Mosquera W, Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases? Am J Therapeutic 2008; 15:362-372.
91. Rueda-Clausen C, Silva F, Lopez-Jaramillo P. Epidemic of obesity and overweigh in Latin America and the Caribbean. Int J Cardiol 2008; 125:111-112.
92. Rueda-Clausen CF, Lahera V, Calderon J, Bolivara IC, Castilloc VR, Gutierrez M, et al. The presence of abdominal obesity is associated with changes in vascular function independently of other cardiovascular risk factors. Int J Cardiol 2008 [published online 15 October 2008]. http://www.internationaljournalofcardiology.com/article/S01 67-5273(08)01012-7/ Abstract.
93. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu K, Dumitrascu D, et al., for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
94. Mancia G, Omboni S, Parati G, Clement DL, Haley WE, Rahman SN, etal. Twenty-four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001; 19:1755-1763.
95. Mancia G, Omboni S, Ravogli A, Parati G, Zanchetti A. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press 1995; 4:148-156.
96. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Hennig M, et al. Assessment of long-term antihypertensive treatment by clinic an ambulatory blood pressure. Data from the ELSA Study. J Hypertens 2007; 25:1087-1094.
97. Fagard RH, Staessen JA, Thijs L. Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. J Hypertens 1997; 15:1493-1502.
98. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome·a new worldwide definition. Lancet 2005; 366:1059-1062.
99. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Guéret P, Karpov Y, et al., On behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18:1465-1475.
100. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 2007; 25:731-741.
101. Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19:1429-1435.
102. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25:25-35.
103. Neutel JM, Sica DA, Franklin SS. Hypertension control: still not there-how to select the right add-on therapy to reach goal blood pressures. J Clin Hypertens 2007; 9:889-896.
104. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21:973-985.
105. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 111:555-576.
106. Fixler DE, Laird WP, Fitzgerald V, Stead S, Adams R. Hypertension screen-ing in schools: results of the Dallas study. Pediatrics 1979; 63:32-36.
107. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity and the prevalence of hypertension in school-aged children. Pediatrics 2004; 113:475-482.
108. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. J Am Med Assoc 2007; 298:874-879.
109. Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, McNamara PM. Blood pressure aggregation in families. Am J Epidemiol 1979; 110:304-312.
110. Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: the Muscatine study. Pediatrics 1989; 84:633-641.
111. Bao W, Threefoot SA, Srinivasan SR, Berenson GS. Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens 1995; 8:657-665.
112. Hornsby JL, Mongan PF, Taylor AT, Treiber FA. White coat hypertension in children. J Fam Pract 1991; 33:61 7-623.
113. Sorof JM, Portman RJ. White coat hypertension in children with elevated casual blood pressure. J Pediatr 2000; 137:493-497.
114. Wühl E, Witte K, Soergel M, Mehls O, Schaefer F, on behalf of the German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 2002; 20:1995-2007.
115. Brandao AP, Brandao AA, Araujo EM, Oliveira RC. Familial aggregation of arterial blood pressure and possible genetic influence. Hypertension 1992; 19 (Suppl 2):214-217.
116. Lurbe E, Torro I, Aguilar F, Alvarez J, Alcon J, Pascual JM, Redon J. Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents. Hypertension 2008; 51:635-641.
117. He FJ, Marrero NM, Mac Gregor GA. Salt intake is related to soft drink consumption in children and adolescents: a link to obesity? Hypertension 2008; 51:629-634.
118. Dolea C, AbouZahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. Evidence and information for policy (EIP). Geneva: World Health Organization; 2003. http://www.who.int/healthinfo/statistics/bod- hypertensivedisordersofpregnancy.pdf.
119. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183:S1-S22.#@
120. Red-Horse K, Zhou Y, Genbacev O, Prakobphol A, Foulk R, McMaster M, Fi SJ. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004; 114:744-754.
121. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Ananth Karumanchi S, Quaggin S, et al. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004; 15:2440-2448.
122. Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011-1016.
123. Lopez-Jaramillo P, Garcia R, Lopez M. Preventing pregnancy induced hypertension: are there regional differences for this global problem? J Hypertens 2005; 23:1121-1129.
124. Garcia R, Celedón J, Sierra J, Alarcón M, Luengas C, Silva F, Lopez-Jaramillo P. Raised C-reactive protein and impaired flow mediated vasodilation precede the development of preeclampsia. Am J Hypertens 2007; 20:98-103.
125. Terán E, Escudero C, Moya W, Florez M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with preeclampsia. Int J Gynaecol Obstet 2001; 75:243-249.
126. Herrera JA, Parra B, Herrera E, Botero JE, Arce RM, Contreras A, Lopez-Jaramillo P. Periodontal disease severity is related to high levels of C-reactive protein in preeclampsia. J Hypertens 2007; 25:1459-1464.
127. Sierra-Laguado J, Garcia RG, Celedon J, Arenas-Mantilla M, Pradilla LP, Camacho PA, Lopez-Jaramillo P. Determination of insulin resistance using the homeostatic model assessment (HOMA) and its relation with the risk of developing pregnancy-induced hypertension. Am J Hypertens 2007; 20:437-442.
128. Knight M, Duley L, Hendersons-Smart DJ, King JF. Antiplatelet agents and preeclampsia (Chochrane review). The Cochrane Library, issue 1, Oxford, update software, 2000.
129. Belizan JM, Villar J. The relationship between calcium intake and edema-, proteinuria-, and hypertension-getosis: an hypothesis. Am J Clin Nutr 1980; 33:2202-2210.
130. López-Jaramillo P, Narváez M, Weigel M, Yépez R. Calcium supplementation reduces the risk of pregnancy induced hypertension in an Andean population. Br J Obstet Gynecol 1989; 96:648-655.
131. Villar J, Abdel-Aleem H, Merialdi M, Mathai M, Ali MM, Zavaleta N, et al. World Health Organization Calcium Supplementation for the Prevention of Preeclampsia Trial Group: World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol 2006; 194:639-649.
132. Hofmeyr GJ, Atallah AN, Duley L Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2006; 3:CD001059.
133. Herrera JA, Chaudhuri G, López-Jaramillo P. Is infection a major risk factor for preeclampsia? MedHyotheses 2001; 57:393-397.
134. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs C, van Geijn HP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173:1042-1048.
135. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9-13.
136. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension 2008; 51:960-969.
137. Cunniff C, Jones KL, Phillipson J, Benirschke K, Short S, Wujek J. Oligohydramnios sequence and renal tubular malformation associated with maternal enalapril use. Am J Obstet Gynecol 1990; 162:187-189.
138. Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 1991; 78:128-135.
139. Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by bypertension. Am J Hypertens 1999; 12:541-547.
140. Stone JH. HELLP syndrome: hemolysis, elevated liver enzymes, and low platelets. JAMA 1998; 280:559-562.
141. Aagaard-Tillery KM, Belfort MA. Eclampsia: morbidity, mortality, and management. Clin Obstet Gynecol 2005; 48:12-23.
142. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 2005; 105:402-410.
143. Magpie Trial Collaborative Group. Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877-1890.
144. Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002; 21:85-95.
145. Arnadottir GA, Geirsson RT, Arngrimsson R, Jonsdottir LS, Olafsson O. Cardiovascular death in women who had hypertension in pregnancy: a case-control study. Br J Obstet Gynecol 2005; 112:286-292.
146. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after preeclampsia: population based cohort study. BMJ 2001; 323:1213-1217.
147. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 2001; 357:2002-2006.
148. Barker DJ, Bagby SP, Hanson MA. Mechanisms of disease: in utero programming in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2:700-707.
149. Franklin SS, Gustin IVM, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96:308-315.
150. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetière P, Guize J. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415.
151. Silagy CA, McNeil JJ, Farish S, McGrath BP. Comparison of repeated measurement of ambulatory and clinic blood pressure readings in isolated systolic hypertension. Clin Exp Hypertens 1993; 15:895-909.
152. Wiinberg N, Høegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, et al. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens 1995; 8:978-986.
153. SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
154. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
155. Medical Research Council trial of treatment of hypertension in older adults: principal, results. MRC Working Party. BMJ 1992; 304:405-412.
156. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
157. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16:1823-1829.